{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T23:11:06Z","timestamp":1648854666866},"reference-count":60,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2005,6]]},"abstract":"<jats:p>O tratamento da doen\u00e7a de Graves (DG) com drogas antitireoidianas (DAT) associa-se \u00e0 remiss\u00e3o da doen\u00e7a em metade dos indiv\u00edduos tratados por no m\u00ednimo 6 meses, e o \u00edndice de recidiva \u00e9 alto, variando de 60 a 80%. A presen\u00e7a de fatores progn\u00f3sticos de sucesso do tratamento medicamentoso da DG \u00e9 tema de discuss\u00e3o na literatura. Neste estudo avaliamos a incid\u00eancia de remiss\u00e3o e recidiva em resposta ao tratamento cl\u00ednico da DG com diferentes esquemas de tratamento com as duas DAT dispon\u00edveis no Brasil (propiltiouracil - PTU e metimazol - MMI), bem como determinar a presen\u00e7a de poss\u00edveis fatores preditivos de remiss\u00e3o e recidiva da doen\u00e7a e o perfil de efeitos colaterais. Revimos, no Hospital Universit\u00e1rio Clementino Fraga Filho (HUCFF), prontu\u00e1rios de todos os pacientes submetidos ao tratamento cl\u00ednico da DG (sem hist\u00f3ria de tratamento pr\u00e9vio) por pelo menos 6 meses e seguidos ap\u00f3s a suspens\u00e3o da DAT por no m\u00ednimo 12 meses. Foram identificados 127 pacientes (idades de 18 a 88 anos; m\u00e9dia 39,3\u00b112,8), nos quais remiss\u00e3o da doen\u00e7a foi observada em 58 (45,7%) e recidiva em 31 deles (53,4%), num per\u00edodo m\u00e9dio de 14,5\u00b116,1 meses. Sexo, idade e tempo de dura\u00e7\u00e3o dos sintomas antes do tratamento cl\u00ednico n\u00e3o interferiram significativamente sobre as taxas de remiss\u00e3o e recidiva, enquanto a presen\u00e7a de b\u00f3cio &gt;40 gramas, oftalmopatia de Graves (OG) e uso de doses di\u00e1rias de DAT &gt;600mg de PTU \/ 60mg de MMI influenciaram negativamente a taxa de remiss\u00e3o. Al\u00e9m disso, pacientes que apresentaram n\u00edveis de TSH &lt;0,4\u00b5IU\/mL entre 4 e 5 semanas ap\u00f3s a suspens\u00e3o da DAT apresentaram maior probabilidade cumulativa de recidiva da doen\u00e7a. Nossos resultados confirmam que a taxa de remiss\u00e3o em longo prazo da DG tratada com DAT \u00e9 relativamente baixa. Conclu\u00edmos que a combina\u00e7\u00e3o de oftalmopatia, b\u00f3cio &gt;40g e uso de dose di\u00e1ria de PTU &gt;600mg ou MMI &gt;60mg relacionou-se fortemente \u00e3341; aus\u00eancia de remiss\u00e3o da DG. Ademais, observamos que a dosagem de TSH entre 4 e 5 semanas ap\u00f3s a suspens\u00e3o da DAT parece ser uma ferramenta \u00fatil na determina\u00e7\u00e3o da chance de remiss\u00e3o ou recidiva da doen\u00e7a.<\/jats:p>","DOI":"10.1590\/s0004-27302005000300013","type":"journal-article","created":{"date-parts":[[2006,1,9]],"date-time":"2006-01-09T17:44:32Z","timestamp":1136828672000},"page":"410-419","source":"Crossref","is-referenced-by-count":0,"title":["Avalia\u00e7\u00e3o do tratamento cl\u00ednico da doen\u00e7a de Graves"],"prefix":"10.1590","volume":"49","author":[{"given":"Maria Claudia","family":"Peixoto","sequence":"first","affiliation":[{"name":"UFRJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Medina","family":"Coeli","sequence":"additional","affiliation":[{"name":"UFRJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rio","family":"Vaisman","sequence":"additional","affiliation":[{"name":"UFRJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","series-title":"Williams textbook of endocrinology","first-page":"443","volume-title":"The thyroid gland","author":"Larsen PR","year":"1998","edition":"9th"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJM199406163302407","article-title":"Drug Therapy: The management of hyperthyroidism","volume":"330","author":"Franklin JA","year":"1994","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref3","series-title":"Basic & clinical endocrinology","first-page":"238","volume-title":"The thyroid gland","author":"Greespan FS","year":"2001","edition":"6th"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM197707282970401","article-title":"Short-term anthithyroid drug therapy for the thyrotoxicosis of Graves' disease","volume":"297","author":"Greer MA","year":"1977","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/thy.1997.7.369","article-title":"Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment","volume":"7","author":"Vitti P","year":"1997","journal-title":"Thyroid","ISSN":"http:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0889-8529(18)30484-5","article-title":"Management of Graves' hyperthyroidism","volume":"16","author":"Orgiazzi J","year":"1987","journal-title":"Endocrinol Metab Clin North Am","ISSN":"http:\/\/id.crossref.org\/issn\/0889-8529","issn-type":"print"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1089\/105072502761016467","article-title":"Reduction of the risk of relapse after withdrawal of medical therapy for Graves' disease","volume":"12","author":"Orgiazzi J","year":"2002","journal-title":"Thyroid","ISSN":"http:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"ref8","series-title":"Cl\u00ednica m\u00e9dica: Doen\u00e7as da tire\u00f3ide","first-page":"33","volume-title":"Tireotoxicose","author":"Vaisman M","year":"2003","edition":"1\u00aa"},{"key":"ref9","series-title":"Goodman and Gilman's The pharmacological basis of therapeutics","first-page":"906","volume-title":"Thyroid and antithyroid drugs","author":"Haynes Jr RC","year":"1990","edition":"8th"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0889-8529(05)70308-X","article-title":"Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease","volume":"27","author":"Cooper DS","year":"1998","journal-title":"Endocrinol Metab Clin North Am","ISSN":"http:\/\/id.crossref.org\/issn\/0889-8529","issn-type":"print"},{"key":"ref11","first-page":"409","article-title":"Prediction of outcome in graves' disease after carbimazole treatment","volume":"59","author":"Weetman AP","year":"1986","journal-title":"Q J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0033-5622","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2265.1995.tb02030.x","article-title":"Response to methimazole in Graves' disease","volume":"43","author":"Benker G","year":"1995","journal-title":"Clin Endocrinol"},{"key":"ref13","first-page":"307","article-title":"Remission of Graves' hyperthyroidism treated with methimazole","volume":"54","author":"Bolanos F","year":"2002","journal-title":"Rev Invest Clin","ISSN":"http:\/\/id.crossref.org\/issn\/0034-8376","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1210\/jcem-55-6-1138","article-title":"Follow-up comparison of short-term versus 1-year antithyroid drug therapy for the thyrotoxicosis of Graves' disease","volume":"55","author":"Bouma DJ","year":"1982","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1530\/acta.0.1220722","article-title":"Factors influencing the outcome of thyrostatic drug therapy in Graves'disease","volume":"122","author":"Winsa B","year":"1990","journal-title":"Acta Endocrinol (Copenh)","ISSN":"http:\/\/id.crossref.org\/issn\/0001-5598","issn-type":"print"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1530\/acta.0.1110039","article-title":"Goitre size and outcome of medical treatment of Graves' disease","volume":"111","author":"Laurberg P","year":"1986","journal-title":"Acta Endocrinol (Copenh)","ISSN":"http:\/\/id.crossref.org\/issn\/0001-5598","issn-type":"print"},{"key":"ref17","first-page":"175","article-title":"Prediction of remission after antithyroid drug treatment in Graves' disease","volume":"66","author":"Young ET","year":"1988","journal-title":"Q J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0033-5622","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1530\/acta.0.1200689","article-title":"Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease","volume":"120","author":"Schleusener H","year":"1989","journal-title":"Acta Endocrinol (Copenh)","ISSN":"http:\/\/id.crossref.org\/issn\/0001-5598","issn-type":"print"},{"key":"ref19","first-page":"777","article-title":"Clinical evolution of a cohort of patients with Graves-Basedow disease treated with metimazole","volume":"118","author":"De Luis DA","year":"2002","journal-title":"Med Clin (Barc)","ISSN":"http:\/\/id.crossref.org\/issn\/0025-7753","issn-type":"print"},{"key":"ref20","first-page":"2410","article-title":"Medical therapy of Graves' disease: Does thyroxine prevent recurrence of hyperthyroidism?","volume":"82","author":"Lucas A","year":"1997","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/eje.0.1470583","article-title":"Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease","volume":"147","author":"Nedrebo BG","year":"2002","journal-title":"Eur J Endocrinol","ISSN":"http:\/\/id.crossref.org\/issn\/0804-4643","issn-type":"print"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1575-0922(02)74425-2","article-title":"Factores prognosticos de recidiva, presentes en el momento del diagn\u00f3stico del hipertiroidismo em la enfermedad de Graves-Basedow tratada com antitiroideos","volume":"49","author":"Hernando CA","year":"2002","journal-title":"Endocrinologia y Nutricion"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1210\/jc.2003-030185","article-title":"Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies","volume":"88","author":"Cooper DS","year":"2003","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.7326\/0003-4819-124-5-199603010-00005","article-title":"Association between the DRB1*08032 histocompability antigen and methimazole-induced agranulocytosis in Japanese patients with Graves' disease","volume":"124","author":"Tamai H","year":"1996","journal-title":"Ann Intern Med","ISSN":"http:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2265.1998.00554.x","article-title":"Is there a methimazole dose effect on remission rate in Graves' disease?: Results from a long-term prospective study","volume":"49","author":"Benker G","year":"1998","journal-title":"Clin Endocrinol (Oxf)","ISSN":"http:\/\/id.crossref.org\/issn\/0300-0664","issn-type":"print"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1210\/jcem-57-3-563","article-title":"Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism","volume":"57","author":"Romaldini JH","year":"1983","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref27","first-page":"2986","article-title":"Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine - a prospective, randomized study. Thyroid Study Group","volume":"81","author":"Torring O","year":"1996","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/105072502321085225","article-title":"Relapse of Graves' disease after sucessful outcome antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine","volume":"12","author":"Hoermann R","year":"2002","journal-title":"Thyroid","ISSN":"http:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/thy.2000.10.891","article-title":"Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulation antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment","volume":"10","author":"Takasu N","year":"2000","journal-title":"Thyroid","ISSN":"http:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1532-5415.1994.tb04973.x","article-title":"Age-related therapeutic response to antithyroid drug in patients with hyperthyroid Graves' disease","volume":"42","author":"Yamada T","year":"1994","journal-title":"J Am Geriatr Soc","ISSN":"http:\/\/id.crossref.org\/issn\/0002-8614","issn-type":"print"},{"key":"ref31","first-page":"1038","article-title":"Age and gender predict the outcome of treatment for Graves' hyperthyroidism","volume":"85","author":"Allahabadia A","year":"2000","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-92-4-488","article-title":"Thionamide therapy in Graves' disease: relation of relapse rate to duration of therapy","volume":"92","author":"Tamai H","year":"1980","journal-title":"Ann Intern Med","ISSN":"http:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF03343979","article-title":"Does smoking increase relapse rates in Graves' disease?","volume":"25","author":"Kimball LE","year":"2002","journal-title":"J Endocrinol Invest","ISSN":"http:\/\/id.crossref.org\/issn\/0391-4097","issn-type":"print"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1210\/jcem-70-3-675","article-title":"Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration","volume":"70","author":"Allannic H","year":"1990","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/105072502753451995","article-title":"Smoking as a risk factor for Graves' disease, toxic nodular goiter, and autoimmune hypothyroidism","volume":"12","author":"Vestergaard P","year":"2002","journal-title":"Thyroid","ISSN":"http:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1530\/eje.0.1440475","article-title":"Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study","volume":"144","author":"Glinoer D","year":"2001","journal-title":"Eur J Endocrinol","ISSN":"http:\/\/id.crossref.org\/issn\/0804-4643","issn-type":"print"},{"key":"ref37","first-page":"377","article-title":"The effects of smoking on remission and relapse of Graves' disease","volume":"46","author":"Unuvar N","year":"1997","journal-title":"Clin Endocrinol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/eje.0.1420117","article-title":"Medical therapy of Graves' disease: effect on remission rates of methimazole alone and in combination with triiodothyronine","volume":"142","author":"Raber W","year":"2000","journal-title":"Eur J Endocrinol","ISSN":"http:\/\/id.crossref.org\/issn\/0804-4643","issn-type":"print"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1210\/jcem-62-5-980","article-title":"Serum triidothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease","volume":"62","author":"Takamatsu J","year":"1986","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/thy.1996.6.29","article-title":"Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompability complex antigens, soluble interleukin-2 receptor, and beta-2 microglobulin in patients with Graves' disease","volume":"6","author":"Escobar-Morreale HF","year":"1996","journal-title":"Thyroid","ISSN":"http:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/thy.1998.8.119","article-title":"The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs","volume":"8","author":"Michelangeli V","year":"1998","journal-title":"Thyroid","ISSN":"http:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1530\/acta.0.1260128","article-title":"Thyroid hipoechogenic pattern at ultrasonography as a tool for predicting recurrence of hyperthyroidism after medical treatment in patients with Graves' disease","volume":"126","author":"Vitti P","year":"1992","journal-title":"Acta Endocrinol (Copenh)","ISSN":"http:\/\/id.crossref.org\/issn\/0001-5598","issn-type":"print"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1365-2265.1996.d01-1563.x","article-title":"Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?","volume":"45","author":"Zingrillo M","year":"1996","journal-title":"Clin Endocrinol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1210\/jcem-50-1-144","article-title":"Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relantionship to relapse:a prospective study","volume":"50","author":"Teng CS","year":"1980","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref45","first-page":"98","article-title":"Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease","volume":"78","author":"Feldt-Rasmussen U","year":"1994","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2265.2001.01197.x","article-title":"Clinical value of a new TSH binding inibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease: Comparison with thyroid stimulating antibody bioassay","volume":"54","author":"Maugendre D","year":"2001","journal-title":"Clin Endocrinol (Oxf)","ISSN":"http:\/\/id.crossref.org\/issn\/0300-0664","issn-type":"print"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1210\/edrv-9-1-106","article-title":"Autoantibodies to the thyrotropin receptor","volume":"9","author":"Smith BR","year":"1988","journal-title":"Endoc Rev"},{"key":"ref48","first-page":"45","article-title":"Thyroid tests for the clinical biochemist and physician: Thyroid autoantibodies","volume":"13","author":"Demers LM","year":"2003","journal-title":"Thyroid","ISSN":"http:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2265.1995.tb02919.x","article-title":"A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs","volume":"43","author":"Kawai K","year":"1995","journal-title":"Clin Endocrinol (Oxf)","ISSN":"http:\/\/id.crossref.org\/issn\/0300-0664","issn-type":"print"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1210\/jcem.83.11.5056-1","article-title":"Thyroid controversy: Stimulating antibodies","volume":"83","author":"Davies TF","year":"1998","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/pgmj.71.834.222","article-title":"Role of TSH measurements in predicting the outcome of treatment for Graves' disease following drug therapy","volume":"71","author":"Wood WE","year":"1995","journal-title":"Postgrad Med J","ISSN":"http:\/\/id.crossref.org\/issn\/0032-5473","issn-type":"print"},{"key":"ref52","first-page":"21","article-title":"Antithyroid drug-induced immunomodulation in Graves' disease patients","volume":"56","author":"Lechpammer M","year":"2002","journal-title":"Acta Med Croatica","ISSN":"http:\/\/id.crossref.org\/issn\/1330-0164","issn-type":"print"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/thy.2000.10.527","article-title":"Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves' disease","volume":"10","author":"Mitsiades N","year":"2000","journal-title":"Thyroid","ISSN":"http:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"ref54","first-page":"2470","article-title":"Methimazole has no dose-related effect on the intensity of the intrathyroidal autoimmune process in relapsing Graves' disease","volume":"80","author":"Paschke R","year":"1995","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/qjmed\/89.5.381","article-title":"Do higher doses of carbimazole improve remission in Graves' disease?","volume":"89","author":"Wilson R","year":"1996","journal-title":"Q J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0033-5622","issn-type":"print"},{"key":"ref56","first-page":"928","article-title":"Effects of chronic iodine admistration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism","volume":"76","author":"Roti E","year":"1993","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref57","first-page":"1526","article-title":"A prospective randomized trial of antithyroid drug dose in Graves' disease therapy","volume":"76","author":"Reinwein D","year":"1993","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref58","first-page":"79","article-title":"A prospective randomized trial of methimazole dose effects on remission rate in Graves'disease","volume":"15","author":"Benker G","year":"1992","journal-title":"J Endocrinol Invest","ISSN":"http:\/\/id.crossref.org\/issn\/0391-4097","issn-type":"print"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1530\/acta.0.1190139","article-title":"Treatment of hyperthyroidism with a small single daily dose of methimazole","volume":"119","author":"Mashio Y","year":"1988","journal-title":"Acta Endocrinol (Copenh)","ISSN":"http:\/\/id.crossref.org\/issn\/0001-5598","issn-type":"print"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1210\/jcem-63-1-125","article-title":"Treatment of hyperthyroidism with a small single daily dose of methimazole","volume":"63","author":"Shiroozu A","year":"1986","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v49n3\/a13v49n3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,14]],"date-time":"2019-04-14T03:04:48Z","timestamp":1555211088000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302005000300013&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0004-27302005000300013"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302005000300013","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}